Raloxifene Reverses Bone Loss in Postmenopausal Women with Mild Asymptomatic Primary Hyperparathyroidism
Authors:
- 1 January 2001
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 16 (1) , 189-190
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With RaloxifeneResults From a 3-Year Randomized Clinical TrialJAMA, 1999
- Raloxifene and Estrogen: Comparative Bone-Remodeling KineticsThe Journal of Clinical Endocrinology & Metabolism, 1997
- Effect of Hormone Replacement Therapy on Bone Mineral Density in Postmenopausal Women with Mild Primary HyperparathyroidismAnnals of Internal Medicine, 1996
- Estrogen replacement may be an alternative to parathyroid surgery for the treatment of osteoporosis in elderly postmenopausal women presenting with primary hyperparathyroidism: A preliminary reportOsteoporosis International, 1996
- A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal womenJournal of Bone and Mineral Research, 1996
- Evidence for a Renal Calcium Leak in Postmenopausal WomenThe Journal of Clinical Endocrinology & Metabolism, 1991